
Li N. Komatsu
Examiner (ID: 14374, Phone: (571)270-3534 , Office: P/1676 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1654, 1658, 1676 |
| Total Applications | 931 |
| Issued Applications | 489 |
| Pending Applications | 126 |
| Abandoned Applications | 345 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19417377
[patent_doc_number] => 20240293500
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => PEPTIDE HAVING ANTICANCER ACTIVITY, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/574671
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4298
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18574671
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/574671 | PEPTIDE HAVING ANTICANCER ACTIVITY, AND USE THEREOF | Jun 27, 2022 | Pending |
Array
(
[id] => 17981223
[patent_doc_number] => 20220347259
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => STABILIZED PEPTIDE COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/851339
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9284
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851339
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/851339 | Stabilized peptide composition | Jun 27, 2022 | Issued |
Array
(
[id] => 18091209
[patent_doc_number] => 20220409550
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => PD-1-DECORATED NANOCAGES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/843418
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11027
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843418
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843418 | PD-1-DECORATED NANOCAGES AND USES THEREOF | Jun 16, 2022 | Pending |
Array
(
[id] => 19389415
[patent_doc_number] => 20240279285
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => Rippled Antiparallel Cross-Beta Dimers and Related Materials, Compositions and Methods
[patent_app_type] => utility
[patent_app_number] => 18/570390
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13570
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18570390
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/570390 | Rippled Antiparallel Cross-Beta Dimers and Related Materials, Compositions and Methods | Jun 16, 2022 | Pending |
Array
(
[id] => 19457690
[patent_doc_number] => 12098170
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-24
[patent_title] => Surface layer protein a (SlpA) as a therapeutic agent for the treatment of inflammatory diseases
[patent_app_type] => utility
[patent_app_number] => 18/568888
[patent_app_country] => US
[patent_app_date] => 2022-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 46
[patent_no_of_words] => 18332
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568888
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/568888 | Surface layer protein a (SlpA) as a therapeutic agent for the treatment of inflammatory diseases | Jun 9, 2022 | Issued |
Array
(
[id] => 18842683
[patent_doc_number] => 20230405087
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-12-21
[patent_title] => ACYLATED GLP-1/GLP-2 DUAL AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/834062
[patent_app_country] => US
[patent_app_date] => 2022-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17158
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 414
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834062
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/834062 | ACYLATED GLP-1/GLP-2 DUAL AGONISTS | Jun 6, 2022 | Pending |
Array
(
[id] => 18842683
[patent_doc_number] => 20230405087
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2023-12-21
[patent_title] => ACYLATED GLP-1/GLP-2 DUAL AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/834062
[patent_app_country] => US
[patent_app_date] => 2022-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17158
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 414
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834062
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/834062 | ACYLATED GLP-1/GLP-2 DUAL AGONISTS | Jun 6, 2022 | Pending |
Array
(
[id] => 19379353
[patent_doc_number] => 20240269223
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-15
[patent_title] => PROPHYLACTIC OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE
[patent_app_type] => utility
[patent_app_number] => 18/570198
[patent_app_country] => US
[patent_app_date] => 2022-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5244
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18570198
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/570198 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE | May 30, 2022 | Pending |
Array
(
[id] => 17982582
[patent_doc_number] => 20220348618
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/747788
[patent_app_country] => US
[patent_app_date] => 2022-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22716
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17747788
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/747788 | COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF | May 17, 2022 | Abandoned |
Array
(
[id] => 17836463
[patent_doc_number] => 20220273768
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => INTRANASAL LEPTIN COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTION OF OPIOID INDUCED RESPIRATORY DEPRESSION IN OBESITY
[patent_app_type] => utility
[patent_app_number] => 17/747905
[patent_app_country] => US
[patent_app_date] => 2022-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20124
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17747905
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/747905 | INTRANASAL LEPTIN COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTION OF OPIOID INDUCED RESPIRATORY DEPRESSION IN OBESITY | May 17, 2022 | Pending |
Array
(
[id] => 18149133
[patent_doc_number] => 20230022990
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => COMPOSITIONS OF GROWTH FACTOR FOR THE TREATMENT OF EYE DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/743488
[patent_app_country] => US
[patent_app_date] => 2022-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21362
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 1
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17743488
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/743488 | COMPOSITIONS OF GROWTH FACTOR FOR THE TREATMENT OF EYE DISEASE | May 12, 2022 | Pending |
Array
(
[id] => 18422016
[patent_doc_number] => 20230176480
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => POLYPEPTIDE, PHOTORESIST COMPOSITION INCLUDING THE SAME, AND METHOD OF FORMING PATTERN USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/741692
[patent_app_country] => US
[patent_app_date] => 2022-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7464
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17741692
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/741692 | Polypeptide, photoresist composition including the same, and method of forming pattern using the same | May 10, 2022 | Issued |
Array
(
[id] => 18161996
[patent_doc_number] => 20230028588
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS
[patent_app_type] => utility
[patent_app_number] => 17/740202
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19167
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740202
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/740202 | PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS | May 8, 2022 | Abandoned |
Array
(
[id] => 17851898
[patent_doc_number] => 20220281940
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => MODIFIED FOLLICLE-STIMULATING HORMONE AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/662312
[patent_app_country] => US
[patent_app_date] => 2022-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8209
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17662312
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/662312 | MODIFIED FOLLICLE-STIMULATING HORMONE AND METHODS OF USING THE SAME | May 5, 2022 | Pending |
Array
(
[id] => 17828537
[patent_doc_number] => 20220265841
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
[patent_app_type] => utility
[patent_app_number] => 17/737471
[patent_app_country] => US
[patent_app_date] => 2022-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24321
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737471
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/737471 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | May 4, 2022 | Abandoned |
Array
(
[id] => 19263465
[patent_doc_number] => 20240207162
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => CARGO MOLECULE TRANSDUCTION DOMAIN RMAD1, VARIANT THEREOF, RECOMBINANT CARGO MOLECULE, AND METHOD FOR TRANSDUCING CARGO MOLECULE USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/288824
[patent_app_country] => US
[patent_app_date] => 2022-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8670
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18288824
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/288824 | CARGO MOLECULE TRANSDUCTION DOMAIN RMAD1, VARIANT THEREOF, RECOMBINANT CARGO MOLECULE, AND METHOD FOR TRANSDUCING CARGO MOLECULE USING SAME | May 2, 2022 | Pending |
Array
(
[id] => 18036206
[patent_doc_number] => 20220380421
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => BROAD SPECTRUM INHIBITORS OF CRISPR-CAS9
[patent_app_type] => utility
[patent_app_number] => 17/734775
[patent_app_country] => US
[patent_app_date] => 2022-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13793
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734775
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/734775 | BROAD SPECTRUM INHIBITORS OF CRISPR-CAS9 | May 1, 2022 | Abandoned |
Array
(
[id] => 18019061
[patent_doc_number] => 20220370560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => PTD-SMAD7 THERAPEUTICS
[patent_app_type] => utility
[patent_app_number] => 17/727579
[patent_app_country] => US
[patent_app_date] => 2022-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727579
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/727579 | PTD-SMAD7 THERAPEUTICS | Apr 21, 2022 | Abandoned |
Array
(
[id] => 19248706
[patent_doc_number] => 20240199693
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => HEPTAPEPTIDE AMIDES FOR USE IN THE TREATMENT OF HMGB1-DEPENDENT DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/287512
[patent_app_country] => US
[patent_app_date] => 2022-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6135
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287512
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/287512 | HEPTAPEPTIDE AMIDES FOR USE IN THE TREATMENT OF HMGB1-DEPENDENT DISEASES | Apr 13, 2022 | Pending |
Array
(
[id] => 19263664
[patent_doc_number] => 20240207361
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => ERYTHROPOIETIN-DERIVED PEPTIDES FOR TREATING RELAPSING-REMITTING MULTIPLE SCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 18/555169
[patent_app_country] => US
[patent_app_date] => 2022-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16664
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18555169
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/555169 | ERYTHROPOIETIN-DERIVED PEPTIDES FOR TREATING RELAPSING-REMITTING MULTIPLE SCLEROSIS | Apr 13, 2022 | Pending |